Abstract
To explore the differences in glucose-lipid metabolism profiles among the 3 TKIs, we designed a retrospective study to compare the onset of hyperglycaemia, hypertriglyceridemia, hypercholesterolemia and hyper-low density lipoprotein (LDL)-cholesterolemia in the patients with normal baseline glucose-lipid profiles and had no medical record of cardio- or cerebro-vascular diseases and/or metabolic syndrome diseases, and identify variables associated with them. 370 chronic myeloid leukaemia patients receiving dasatinib, nilotinib or imatinib therapy ≥3 months were retrospectively reviewed. During TKI-therapy, the mean fasting glucose, triglyceride, cholesterol, and LDL-cholesterol levels increased significantly in both dasatinib and nilotinib cohorts compared with the imatinib cohort. In multivariate analyses, dasatinib was the factor significantly associated with both poor hyperglycaemia- and hypertriglyceridemia-free survival. In addition, nilotinib was significantly associated with more occurrences of hyperglycaemia and hypercholesterolemia; increasing age was significantly associated with more occurrences of hyperglycaemia and hypertriglyceridemia. We concluded that dasatinib, similar to nilotinib, has the adverse impact on glucose-lipid metabolism compared with imatinib.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / pharmacology
-
Cholesterol, LDL / blood
-
Dasatinib / adverse effects*
-
Dasatinib / pharmacology
-
Dasatinib / therapeutic use
-
Female
-
Follow-Up Studies
-
Glucose / metabolism*
-
Humans
-
Hyperglycemia / blood
-
Hyperglycemia / chemically induced
-
Hypertriglyceridemia / blood
-
Hypertriglyceridemia / chemically induced
-
Imatinib Mesylate / adverse effects
-
Imatinib Mesylate / pharmacology
-
Imatinib Mesylate / therapeutic use
-
Leukemia, Myeloid, Chronic-Phase / drug therapy*
-
Leukemia, Myeloid, Chronic-Phase / metabolism
-
Lipid Metabolism / drug effects*
-
Male
-
Middle Aged
-
Neoplasm Proteins / antagonists & inhibitors
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects*
-
Protein Kinase Inhibitors / pharmacology
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Pyrimidines / adverse effects
-
Pyrimidines / pharmacology
-
Pyrimidines / therapeutic use
-
Salvage Therapy
-
Young Adult
Substances
-
Antineoplastic Agents
-
Cholesterol, LDL
-
Neoplasm Proteins
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Imatinib Mesylate
-
Protein-Tyrosine Kinases
-
nilotinib
-
Glucose
-
Dasatinib